NCT01790503 - A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2013

Primary Completion Date

November 3, 2017

Study Completion Date

March 4, 2020

Conditions

Patients With Newly Diagnosed Glioblastoma

Interventions

DRUG

PLX3397

RADIATION

Radiation Therapy

DRUG

Temozolomide

Trial Locations (9)

Columbia University Medical Center, New York

James Cancer Hospital/Ohio State University, Columbia

Henry Ford Hospital, Detroit

Northwestern Memorial Hospital, Chicago

Huntsman Cancer Institute University of Utah, Salt Lake City

Seattle Cancer Care Alliance, Seattle

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston